ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.

Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the much-anticipated data from the OCEANIC-AF trial (NCT05643573; Bayer).

This multicentre, international, randomised, phase 3 study compared asundexian with apixaban in patients with atrial fibrillation and a high risk of stroke. Investigators enrolled 14,830 patients from 1,069 locations across various countries. The primary outcome measure was the time to first occurrence of a composite of stroke or systemic embolism.

Data revealed at ESC suggest that asundexian was inferior to apixaban (hazard ratio [HR] 3.79; 95% confidence interval [CI] 2.46-5.83) for stroke and systemic embolism prevention, but was associated with fewer major bleeding events (0.2% vs. 0.7%; HR 0.44; 95% CI 0.34-0.57). 

Recorded on-site at ESC Congress 2024, London.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.